Skip to main content

Dr. Michael J. Hafran, M.D.

Family Medicine (Family Medicine Physician)

  • Medicare participating

At a glance

In the NPI registry since
2006
Medicare patients seen, 2024
30

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Family Medicine Physician primary
    MI license 4301505631 · WI license 49922

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Family Medicine per capita by county →

Medicare patients and services

Medicare patients, 2024
30
Services billed
146
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Device supply with scheduled recording and transmission for remote monitoring of musculoskeletal system, per 30 days41,7097,334
Remote therapeutic monitoring treatment management services by physician or other qualified health care professional, first 20 minutes per calendar month39,2417,165
Remote therapeutic monitoring treatment management services by physician or other qualified health care professional, each additional 20 minutes per calendar month5,0323,354
Set-up and patient education for remote monitoring of therapy3,4373,435
Management using the results of remote vital sign monitoring per calendar month, first 20 minutes41752
Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days24941
Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes24540

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Payments from drug and device companies

In 2025, 3 companies reported 33 payments worth $3,093 in total to this clinician.

By type
Travel and Lodging$2,608
Food and Beverage$449
Education$36.00

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 23, 2025Merck Sharp & Dohme LLC
Sep 23, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$488
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$249
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$249
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$249
Sep 23, 2025Merck Sharp & Dohme LLC
Sep 23, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$238
Sep 24, 2025Merck Sharp & Dohme LLC
Sep 24, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$233
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$218
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$197
Sep 23, 2025Merck Sharp & Dohme LLC
Sep 23, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$126
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$98.00
All 25 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Sep 24, 2025Merck Sharp & Dohme LLC
Sep 24, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$233
Sep 23, 2025Merck Sharp & Dohme LLC
Sep 23, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$488
Sep 23, 2025Merck Sharp & Dohme LLC
Sep 23, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$238
Sep 23, 2025Merck Sharp & Dohme LLC
Sep 23, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$126
Sep 23, 2025Merck Sharp & Dohme LLC
Sep 23, 2025
Travel and Lodging
CARDIOVASCULAR · travel to Atlanta, GA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$97.70
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$249
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$249
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$249
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$218
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$197
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$98.00
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Education
in-kind
$36.00
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$32.37
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$17.43
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$17.43
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$16.97
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$15.30
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$14.94
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
$14.94
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$11.99
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$7.65
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$4.99
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$4.99
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$4.99
Apr 16, 2025Eli Lilly and Company
Apr 16, 2025
Travel and Lodging
travel to MIAMI, FL · in-kind
Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS
$2.49

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Michigan →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 6 companies. The companies reported $2,666,979 in research payments for these studies, mostly to the institutions running them.

  • A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
    Eli Lilly and Company · Active, not recruiting · NCT06643728
  • A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
    Eli Lilly and Company
  • A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight…
    AstraZeneca UK Limited
  • A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
    Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429
  • A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
    Novartis Pharmaceuticals Corporation
  • A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
    Novartis Pharmaceuticals Corporation
  • A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
    Novartis Pharmaceuticals Corporation
  • A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
    Eli Lilly and Company · Withdrawn · NCT06901349
  • A phase 3, 24-week, randomized, double-blind, placebo-controlled, para
    GlaxoSmithKline, LLC.
  • A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
    Amgen Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Family Medicine clinicians in East Lansing

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 29, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1003878000. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.